President Donald Trump says taxing imports will strengthen domestic manufacturing. Hours before announcing new tariffs, his ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Founded in 2012, 10x Genomics (NASDAQ:TXG) is a biotech company developing gene-sequencing solutions based in the US. In a rather competitive market, TXG’s focus has been on single-cell and ...

Institutional investors and hedge funds own 84.68% of the company’s stock. 10x Genomics (NASDAQ:TXG – Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th.

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

TXG) develops single-cell and spatial genomics solutions, enabling researchers to analyze biological systems at high resolution. Free cash flow isn't a prominently featured metric in company ...

Several other equities analysts have also recently commented on TXG. UBS Group cut their price target on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a ...